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ABSTRACT
Lysosomal acid lipase deficiency (LAL-D) is still 
a little recognized genetic disease with significant 
morbidity and mortality in children and adults.
This document provides guidance on when 
to suspect LAL-D and how to diagnose it. It 
is recommended to add lysosomal acid lipase 
deficiency to the list of differential diagnoses of 
sepsis, oncological diseases, storage diseases, 
persistent diarrhea, chronic malnutrition, and 
hemophagocytic lymphohistiocytosis. It should 
also be considered in young patients with 
dyslipidemia and atherosclerosis as well as diseases 
associated with fatty liver and/or hepatomegaly.
LAL-D should be suspected in patients with 
hepatomegaly, hyperlipidemia and/or elevated 
transaminases found during routine checks or 
testing for other conditions, and in patients 
with cryptogenic cirrhosis. At present, there 
is the option of a specific enzyme replacement 
treatment.
Key words: cirrhosis, dyslipidemias, Wolman 
disease, non-alcoholic fatty liver disease, lysosomal 
acid lipase deficiency.
 
http://dx.doi.org/10.5546/aap.2017.eng.287
To cite: Bay L, Cañero Velasco C, Ciocca M, et al. 
Liver disease and dyslipidemia as a manifestation of 
lysosomal acid lipase deficiency (LAL-D). Clinical and 
diagnostic aspects, and a new treatment. An update. 
Arch Argent Pediatr 2017;115(3):287-293.
INTRODUCTION
Liver disease and dyslipidemia are 
frequent findings in everyday practice, 
and common signs of lysosomal acid 
lipase deficiency (LAL-D), a low-
prevalence storage disease. It follows 
an autosomal recessive inheritance 
pattern and is caused by mutations in 
the LIPA gene, located in chromosome 
10q23.2-23.3.1 This enzyme is involved 
in the metabolism and breakdown of 
cholesteryl esters and triglycerides 
that accumulate in different tissue 
cells when the enzyme is reduced 
or  absent .  The  most commonly 
affected organs and systems include 
the liver, spleen, adrenal glands, 
hematopoietic system, vascular 
endothelium, intestines, and lymph 
nodes. The clinical manifestations of 
LAL-D vary depending on age.2 Liver 
involvement and dyslipidemia are the 
prevalent clinical presentations, and 
for this reason some patients may be 
misdiagnosed.
OBJECTIVE
To review LAL-D, its clinical 
manifestations, differential diagnoses, 
diagnostic confirmation, and new 
therapeutic options.
Clinical manifestations
The age at the time of onset, clinical 
spectrum, and disease course vary 
widely. There is a severe infant form 
or Wolman disease,4,5 first described 
in 1956, and a late onset pediatric, 
adolescent, or adult form known 
as cholesteryl ester storage disease 
(CESD), first described in 1963.2 The 
phenotype depends on the type of 
LIPA gene mutation and the severity 
of enzyme deficiency.
The severe form occurs in the first 
months of life, with an almost null 
enzyme activity (LAL) or < 1% of 
normal activity.5 Children appear 
healthy at birth but, between 1 and 2 
months old, they have malaise, failure 
to thrive, progressive malnutrition, 
m a r k e d  a b d o m i n a l  d i s t e n s i o n 
c a u s e d  b y  m a l a b s o r p t i o n  a n d 
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hepatosplenomegaly, recurrent vomiting, chronic 
diarrhea (steatorrhea), and liver involvement with 
rapid development of fibrosis and/or cholestasis 
and/or liver failure. Elevated transaminases 
(50-95% of cases) and hypersplenism (anemia/
t hrombocytopenia )  a re  a l so  observed . 2 
Approximately 50% of patients have bilateral 
calcifications of the adrenal glands.6,7
Cholesterol levels are elevated or normal 
with reduced high-density lipoproteins (HDL) 
and increased very low-density lipoproteins 
(VLDL); triglycerides may be normal or elevated.8 
Developmental delay and/or irritability are 
secondary to malnutrition, overall compromise, 
and hospitalization resulting from the central 
nervous system involvement caused by this 
disease.9 The natural course of this clinical form 
results in death in the first year of life.10-12
The subtype of LAL-D that starts during 
childhood, adolescence, or adulthood implies 
1 -12% of  normal  enzyme act iv i ty ;  l ip id 
accumulation leads to progressive liver damage, 
elevated transaminases, steatosis, fibrosis and/
or cirrhosis. These patients develop chronic 
dyslipidemia, which leads to early atherosclerosis 
(infarction, aneurism, stroke).13-14
In a series of 48 patients with this subtype 
of LAL-D, the median age at the time of disease 
reporting was 5.8 years old (maximum: 46 years 
old); 56% were younger than 20 years old and 
17%, younger than 10 years old. Symptoms 
started before 10 years old in 75% of patients. 
Alanine aminotransferase (ALT), aspartate 
aminotransferase (AST), and gamma-glutamyl 
transferase (GGT) were elevated in 92%, 59%, 
and 20% of patients, respectively. Hepatomegaly, 
which is less common in the early onset subtype, 
was reported in 54% of patients whereas 
splenomegaly was reported in only 23%.16
Dyslipidemia in LAL-D is indistinguishable 
from that occurring in other more common 
etiologies. Total cholesterol, LDL-C, VLDL-C, 
and triglycerides are elevated, and HDL-C is 
reduced.1,4,5 Pediatric patients have shown LDL-C 
≥ 130 mg/dL and HDL-C ≤ 45 mg/dL.11 Cerebral 
infarction and hyperlipidemia have been reported 
at 13 years old, with symptomatic gallbladder 
dysfunction16 (Table 1).
Prevalence
Although more than 40 mutations have been 
described,17 the mutation in exon 8, E8SJM (c.894G 
> A) has been identified in 50-60% of patients 
with the late onset subtype and of European 
descent.18 It was detected in approximately 
1:200 heterozygous healthy German individuals. 
Thus, prevalence may be expected to be 1:40 000 
German newborn infants, and 1:300 000 Hispanics 
and Caucasians.19,20 The number of reported cases 
has been much lower than these estimates, which 
suggests a non-specific clinical course and the 
absence of a characteristic phenotype. No studies 
have been conducted regarding the prevalence of 
LAL-D in Argentina.
Diagnosis of lysosomal acid lipase deficiency 
at the lab
The definitive diagnosis of LAL-D is made 
by demonstrating the deficiency or absence of 
LAL enzyme activity (EC 3.1.1.13) in isolated 
peripheral blood leukocytes or fibroblast cell 
cultures.21 Enzyme determination may also be 
done from blood spots dried on filter paper,22 
which allows for the proper submission of lab 
specimens from remote locations, retrospective 
diagnosis, and population level screening. 
However, if filter paper samples are abnormal, 
results should be confirmed using leukocytes 
or fibroblasts. This test is useful to confirm the 
diagnosis of homozygous individuals, but not 
for heterozygous ones, who may have a normal 
enzyme activity.
The molecular genetic  test  consists  in 
identifying the pathogenic mutations in both 
alleles of the LIPA gene, and is considered 
a supplementary diagnostic test.23 Mutation 
identification is useful to carry out family studies 
and, therefore, provide a diagnosis and genetic 
counseling to heterozygous family members.
Pathophysiology
Acid  l ipase  ac t s  on  hepatocyte  l ip id 
metabolism, and acid lipase deficiency, as 
described from a pathophysiological perspective 
in Figure 1. A, explains dyslipidemia and neutral 
lipid accumulation in the lysosome, resulting in 
liver damage.24
Differential diagnosis
Although there are biochemical and genetic 
tests for the diagnosis of LAL-D, detecting this 
disease depends on clinical suspicion, which is 
low.11,12 Clinical and biochemical manifestations 
are consistent with other cardiovascular, liver or 
metabolic diseases.1,12 LAL-D should be included 
in the list of differential diagnoses of liver 
conditions and dyslipidemias. Given its severe 
morbidity and early mortality, patients should 
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Figure 1. A. Effect of LAL-D on the liver and lipid metabolism. A hepatocyte receptor is responsible for LDL and VLDL cholesterol 
uptake, which are then carried to the lysosome. LAL-D results in cholesterol ester (CE) and triglyceride accumulation, and 
reduces free cholesterol (FC) and fatty acid (FA) production. The reduction in cholesterol increases sterol regulatory-element 
binding protein (SREBP) activity and cholesterol and FA synthesis, thus increasing LDL and VLDL cholesterol levels. The 
reduction in FC decreases liver X receptor (LXR) activation and the expression of ABCA1 transporter, thus reducing cholesterol 
flow to apolipoprotein A1 (ApoA-1) and plasma HDL cholesterol levels. B. Effect of treatment with sebelipase alfa (rhLAL); 
the mannose-6-phosphate (M6P) receptor is responsible for sebelipase alpha uptake, which is carried to the lysosome, where it 
reverses lipid metabolism defects. It prevents hepatocyte lipid accumulation. Modified from Rader D.24
LAL: lysosomal acid lipase; HDL: high-density lipoproteins; LDL: low-density lipoproteins;  
VLDL: very low density lipoproteins; TG: triglycerides.
Table 1. Lysosomal acid lipase deficiency phenotype: from the severe form in infants (Wolman disease) to the late-onset form 
in children, adolescents, and adults (cholesteryl ester storage disease) (modified from Grawoski, 2014)
Clinical signs Newborns and infants Children, adolescents and adults
Age at onset 0-3 months old From childhood to adulthood
Age at death ±6 months old Varied
Hepatomegaly ++++ +/++
Liver fibrosis/cirrhosis ++ +/+++
Splenomegaly +++ +/-
Malabsorption +++ +/-
Emaciation +++ ±
Adrenal calcifications ++ ±
Dyslipidemia ± ++/+++
Cholesteryl ester storage 5-160 times higher than normal 150-350 times higher than normal
Triglyceride storage In the liver: 2-10 times higher than normal 
 In the spleen: 8-100 times higher than normal 
 In the adrenal glands: 1.5-8 times higher than normal 1.5-3 times higher than normal
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be diagnosed quickly, before any permanent 
damage occurs (in the liver, spleen, digestive 
tract, vascular system).11,12 Below we will review 
differential diagnoses.
Visceromegaly in the severe infant presentation 
or Wolman disease is also common in other 
storage diseases (Niemann-Pick disease, Gaucher 
disease, glycogen storage disease type IV). 
In  the  case  of  hemophagocyt ic  lympho-
histiocytosis, similarities have been described 
between this disease and LAL-D25 and other 
oncological diseases. Although these other 
conditions have their own typical phenotypes 
and biochemical features, the severe clinical form 
in the first year of life may be confused with acid 
lipase deficiency.26-31
Adrenal calcifications should be differentiated 
from neuroblastoma and adrenal hemorrhage, 
although in these cases, the lesion is usually 
unilateral.
S e p s i s ,  c o n g e n i t a l  i n f e c t i o n s  w i t h 
visceromegaly, subacute or chronic gastroenteritis, 
malabsorption disorders, Hirschsprung disease, 
and cow’s milk allergy may be confused with 
LAL-D,21 so it should be included in the differential 
diagnosis when any of these more common 
etiologies is not confirmed or if the patient’s course 
does not improve as expected.
LAL-D should be included in the differential 
diagnosis of older patients (children, adolescents 
and adults) with normal weight or overweight, 
elevated levels of total cholesterol and LDL-C, 
low levels of HDL-C, elevated transaminases 
and/or hepatomegaly and/or hepatic steatosis.12
Overweight or obese patients with metabolic 
syndrome,32 elevated transaminases, signs of 
hepatic steatosis in imaging tests, and alcohol 
intake < 140 g/week, it is necessary to rule 
out other muscle or liver diseases besides non-
alcoholic fatty liver disease (NAFLD)/non-
alcoholic steatohepatitis (NASH).32,33
Obesity itself does not warrant looking for 
NAFLD based on elevated transaminases,34 
although LAL-D should be ruled out in those 
patients who lose weight on treatment but 
whose biochemical markers are not modified as 
expected.25,35
As there is no specific biochemical marker 
for NAFLD and NASH, doing a liver biopsy 
has been the recommendation,36,37 although it 
does not provide a definitive diagnosis either. 
Patients with microvesicular steatosis may be 
wrongly diagnosed as having NAFLD35 or NASH. 
At present, NAFLD is the most common cause 
of elevated transaminases during childhood 
and adolescence, resulting from the increase in 
obesity incidence.38,39 Adolescents and adults 
with NAFLD usually have insulin resistance and 
hyperglycemia, but this is not the case in patients 
with LAL-D.40 NAFLD is rare among children 
younger than 3 years old, and uncommon among 
those younger than 10 years old. Table 2 describes 
the characteristics of NAFLD/NASH and LAL-D.
In Latin America, cirrhosis41 is associated with 
chronic alcohol abuse, hepatitis virus (hepatitis C 
virus [HCV]: 29%; hepatitis B virus [HBV]: 27%), 
alterations in liver drainage (19%), NASH (8%), 
and cryptogenic cirrhosis (6%).42
In pediatrics, 5-15% of cirrhosis cases are 
cryptogenic, and LAL-D should be included 
Table 2. Differential diagnosis of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and lysosomal acid lipase 
deficiency (late onset)
 NAFLD/NASH LAL-D (late onset)
Prevalence 20/100 1:40 000
Hepatomegaly +/- +++
Splenomegaly +/- ++
BMI Overweight/obesity Normal/overweight
AST/ALT á 20% in the general population +++
Carbohydrate metabolism Abnormal Normal
Triglycerides á á Normal or á
HDL-C 
LDL-C Normal or á á á
Liver biopsy Macrovesicular steatosis Microvesicular steatosis
NAFLD/NASH: non-alcoholic fatty liver disease/non-alcoholic steatohepatitis; BMI: body mass index;  
ALT: alanine aminotransferase; AST: aspartate aminotransferase; HDL-C: high-density lipoprotein cholesterol;  
LDL-C: low-density lipoprotein cholesterol.
á á
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in screening tests for both children and adults. 
Microvesicular or mixed steatosis of the liver in 
children and adolescents leads to the suspicion 
of Wilson’s disease, rather than LAL-D, because 
steatosis in Wilson’s disease is secondary to 
copper accumulation, although LAL-D should 
also be included in the differential diagnosis.43,35
In the case of early liver failure, LAL-D 
should be included in screening tests in addition 
to tyrosinemia, galactosemia, beta-oxidation 
disorders, neonatal hemochromatosis, and 
mitochondrial diseases.44,45
In the case of LAL-D, the histology of the 
liver shows cholesteryl ester accumulation in 
hepatocytes and Kupffer cells. Almost 50% of 
cases present with septal fibrosis that progresses 
to cirrhosis. A liver transplant may be required 
in the three years following symptom onset.6,11,12 
The histopathological examination is facilitated 
by immunostaining of cathepsin D, a lysosomal 
protein.11
In relation to dyslipidemia, there are national 
recommendations in place for its screening in 
children and adolescents aged 6 to 17.46,47 This 
allows for the detection of hypercholesterolemia 
and its early management. If there is no clear 
family history, and dyslipidemia does not 
improve with regular treatment (diet and physical 
activity to achieve a normal body mass index 
[BMI]), LAL-D should be investigated, as well as 
other causes of secondary hypercholesterolemia.
Pediatric patients with LDL > 130 mg/dL and/
or HDL < 40 mg/dL without a clear family history, 
obesity, or central fat distribution, or with normal 
fasting glucose may have LAL-D48 (Table 3).8
TREATMENT
No effective treatment for LAL-D has been 
established; lipid lowering drugs have been 
poorly effective and failed to improve liver 
involvement.1,11 There is scarce information about 
the history and follow-up of liver transplantation, 
although in the past it has been the only plausible 
option in the case of progression to end-stage liver 
failure.1
In 2015, the use of an enzyme replacement 
therapy with a recombinant human form of the 
lysosomal enzyme (sebelipase) was approved 
for intravenous use every 15 days. A double-
bl ind,  randomized,  mult icenter  c l in ica l 
trial,49 demonstrated a significant decrease 
in transaminases, liver fat as observed in a 
magnetic resonance imaging (MRI) study, and 
hepatomegaly. LDL-C and triglycerides were 
significantly reduced, and HDL-C increased. Only 
a few, mild adverse reactions were reported in 
this study (Figure 1. B).
In a phase 2/3 clinical trial with sebelipase 
alfa in children with the early onset subtype, 5 
out of 9 patients survived beyond 2 years old, 
and 1, beyond 5 years old. Liver disease markers, 
gastrointestinal symptoms, and nutritional status 
improved.50
Although no long-term follow-up has 
been completed for this treatment, given the 
mechanism of action of sebelipase, it may have a 
potential effect on the reduction of liver fibrosis 
and its progression to cirrhosis, as well as on the 
improvement of dyslipidemia and the prevention 
of cardiovascular complications.51 n
Table 3. High-risk populations that should be considered in the screening for lysosomal acid lipase deficiency
Modified from Burton B, JPGN 2015;61:619-625.8
Non obese patients with the following:
- Persistent hepatomegaly
- Elevated transaminases without a definite cause
- High levels of LDL (> 130 mg/dL, 4.1 mmol/L)
- Low levels of HDL (males: < 40 mg/dL; females: < 50 mg/dL)
Obese patients diagnosed with metabolic syndrome and the following:
- Persistent hepatomegaly
- No hyperglycemia
- Elevated transaminases without a definite cause that do not improve with a reduction in BMI
Obese patients who manage to reduce their BMI but whose lipid profile does not improve
Patients with microvesicular steatosis
HDL: high-density lipoproteins; LDL: low-density lipoproteins; BMI: body mass index.
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